Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL
      • CHRONIC PAIN
      • INSOMNIA
      • AUTISM
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL
      •                 - CHRONIC PAIN
      •                 - INSOMNIA
      •                 - AUTISM
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

TechInvest – Zelira obtains key data in cannabis dose escalation study

By Zelira TherapeuticsJuly 14, 2020articles-2020

TechInvest – Zelira obtains key data in cannabis dose escalation study

The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated
Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
22 Dec

This year Zelira achieved a number of key commercial and clinical milestones that marked its successful transition to the ‘Launch, Learn and Develop’ model for rapid commercialisation.
#ZLD #ZLDAF #autism #insomnia #clinicaltrials
https://t.co/B8RNItl4mS

Twitter
Load More...

CONTACT US






Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.